NTLA vs VRTX
NTLA and VRTX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | NTLAINTELLIA THERAPEUTICS, INC. | VRTXVERTEX PHARMACEUTICALS INC / MA |
|---|---|---|
| Market cap | $1.72B | $139.22B |
| P/E (TTM) | — | 35.3 |
| P/B | — | 6.66 |
| P/S | 25.5x | 11.6x |
| Revenue | — | $12.95B(TTM) |
| Revenue growth (YoY) | 16.9% | 8.9% |
| Net income | — | $3.98B(TTM) |
| Earnings growth (YoY) | 20.5% | 838.1% |
| EPS, diluted | — | $15.54(TTM) |
| EBIT margin | -651.7% | 34.8% |
| ROE | -56.7% | 18.9% |
| ROIC | — | 17.4% |
| 1y total return | +1.0% | +30.3% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: NTLA vs VRTX
| Metric | NTLA | VRTX |
|---|---|---|
| End value | $6.2K | $63.5K |
| Total return | -38.0% | +534.6% |
| CAGR | -4.5% | +19.6% |
| Volatility | 78.3% | 32.6% |
| Sharpe | 0.28 | 0.58 |
| Sortino | 0.41 | 0.86 |
| Max drawdown | -96.5% | -41.6% |
Based on 2600 common trading days, 2016-07-05 → 2026-11-04 · risk-free 4.21% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)